株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国におけるバイオ医薬品メーカー上位60社のディレクトリ

China Top 60 Biopharmaceutical Manufacturing Directory - Second Edition

発行 BioPlan Associates, Inc. 商品コード 753441
出版日 ページ情報 英文 366 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。
Back to Top
中国におけるバイオ医薬品メーカー上位60社のディレクトリ China Top 60 Biopharmaceutical Manufacturing Directory - Second Edition
出版日: 2017年02月28日 ページ情報: 英文 366 Pages
概要

当レポートでは、中国のバイオ医薬品施設について調査分析し、詳細なプロファイル (生産能力、歴史、製品、規模、経営、ビジネスフォーカス、製品、R&D、事業・提携戦略、強みと弱み、将来目標など) のほか、既存・将来の施設、上市・治験製品に関する情報も含めて、体系的な情報を提供しています。

第1章 中国のバイオ医薬品製造

第2章 調査手法

第3章 中国のバイオファーマの主要イベント

第4章 中国のバイオ医薬品メーカーの概要

第5章 中国におけるバイオ医薬品組織10社のプロファイル

第6章 付録:中国における新興のバイオファーマ企業

目次
Product Code: ISBN 978-1934-106-31-0

The completely updated, comprehensive Top 60 Directory provides detailed profiles of China biopharmaceutical facilities, including information on their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives. The directory also highlights current and upcoming facilities, and includes information on key marketed and clinical trial products.

“Top 60 Biopharmaceutical Facilities in China Directory” allows readers to keep up-to-date on new and existing biopharmaceutical facilities as the industry continues to grow and expand. This newly updated directory helps you stay aware of current key participants, as well as new and upcoming facilities in this rapidly changing market.

Directory Content

This second edition of BioPlan Associates' facilities directory of major biopharmaceutical manufacturing facilities in China covers facilities with the most bioprocessing capacity (total bioreactor volumes), and those under active construction. Facility information includes:

  • Company ownership, background, management and facility capacity and history.
  • Financial estimates are provided, along with derived data regarding facility size, available partnership resources, etc.

The ranking of companies is based on facility factors including aspects such as:

  • Total liters' capacity
  • Number of employees related to biologics production
  • Number of products in commercial or clinical production.

By the Numbers:

  • 357 pages
  • Over 75+ Chinese-owned biopharmaceutical organizations, plus up-and-coming facilities!
  • Includes recombinant and protein therapeutic biopharmaceutical companies and vaccine manufacturers

Online China Top 60 Database

The Directory also is available as a regularly updated online database featuring monthly updates, new data, re-ranked facilities, and vital capacity, build-out, and staffing information.

Our Team in the News

Vicky Qing XIA, Sr. Project Manager.

MS Biology University of Texas, MBA University of Pittsburgh, has extensive experience in alliance management in China's bio-pharmaceutical industry; has worked with major biopharma facilities in US and China. Her expertise includes analysis of global markets; she also authors biotech publications and newsletters.

Yibing (Eliza) Zhou, Project Director, China.

Yibing Zhou manages pharmaceutical and biotechnology programs in China. She is an editor and author for “Advances in Biopharmaceutical Technology in China” by BioPlan and the Society for Industrial Microbiology. Ms. Zhou holds a Bachelor of Pharmaceutical Chemistry (1987) from the West China University of Medical Sciences (merged into Sichuan University in 2001).

Table of Contents

1. China Biopharmaceutical Manufacturing

2. Study Methodology

  • Table 1: Top 60 Biopharmaceutical Companies in China (By Ranking)

3. Major Events in China Biopharma

  • Table 2: Launch Of Major Biological Products (Mostly mAb), 2006-2016
  • Table 3: New Mab Makers And Chemical Drug Makers Entering mAb Sector

4. Summary of China Biopharmaceutical Manufacturers

  • Table 4: China Biopharmas by Facility Primary Manufacture Type

5. Profiles of 10 Biopharmaceutical Organizations in China

6. Appendix: Emerging Biopharma Companies in China

Back to Top